Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Colorcon
Boehringer Ingelheim
Medtronic
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR LITHIUM CARBONATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lithium Carbonate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000369 ↗ Maintenance Therapies in Bipolar Disorders Completed University of Pittsburgh Phase 3 1997-06-01 The purpose of this study is to see if adding a regimen of individualized psychotherapy can help bipolar I patients who are on lithium. While having a manic or depressed episode patients will be assigned randomly (like tossing a coin) to receive appropriate medication either with or without additional individual psychotherapy. If a patient responds well, he/she will again be assigned randomly to receive further preventative treatment in which medication will be managed either with continued medication clinic visits alone or with additional individual psychotherapy (the patient may not receive the same additional treatment this time). Patient response to treatment will be evaluated throughout the study. If manic/depressive symptoms return at any point during the study, the patient will be treated with appropriate medication and will continue the study. An individual may be eligible for this study if he/she: Has Bipolar I disorder, is experiencing a manic or depressed episode at the time of study entry, and is at least 18 years old.
NCT00000439 ↗ Drug Treatment for Alcoholics With Bipolar Disorder Completed University of Pittsburgh Phase 2 2000-10-01 The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00000439 ↗ Drug Treatment for Alcoholics With Bipolar Disorder Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2000-10-01 The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00005015 ↗ Treatment of Depression in Youth With Bipolar Disorders Terminated National Institute of Mental Health (NIMH) Phase 3 1969-12-31 THIS STUDY HAS BEEN DISCONTINUED. The study is designed to evaluate the safety and efficacy of fluoxetine for treating children and adolescents with Bipolar Disorder who are experiencing an episode of major depression while being treated with a mood stabilizer. The study involves a 2-week assessment period. Patients who are on stable, therapeutic doses of lithium or valproate and continue to have depression will be randomized to a 12-week treatment of fluoxetine or placebo. Those who respond favorably to treatment will be followed openly for an 18-week continuation phase.
NCT00057681 ↗ Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed National Institute of Mental Health (NIMH) Phase 3 2003-02-01 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00057681 ↗ Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed Washington University School of Medicine Phase 3 2003-02-01 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00063362 ↗ Combination Therapy for the Treatment of Bipolar Disorders Terminated National Institute of Mental Health (NIMH) Phase 3 2002-02-01 This study will compare triple and double drug regimens in the treatment of patients with depression, hypomania, or mania.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lithium Carbonate

Condition Name

Condition Name for Lithium Carbonate
Intervention Trials
Bipolar Disorder 26
Major Depressive Disorder 6
Spinal Cord Injuries 5
Depression 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lithium Carbonate
Intervention Trials
Bipolar Disorder 34
Disease 17
Depression 15
Depressive Disorder 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lithium Carbonate

Trials by Country

Trials by Country for Lithium Carbonate
Location Trials
United States 100
Canada 16
China 16
Italy 8
Australia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lithium Carbonate
Location Trials
Pennsylvania 13
Ohio 10
New York 9
California 7
Texas 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lithium Carbonate

Clinical Trial Phase

Clinical Trial Phase for Lithium Carbonate
Clinical Trial Phase Trials
Phase 4 21
Phase 3 16
Phase 2/Phase 3 3
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lithium Carbonate
Clinical Trial Phase Trials
Completed 60
Terminated 11
Unknown status 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lithium Carbonate

Sponsor Name

Sponsor Name for Lithium Carbonate
Sponsor Trials
National Institute of Mental Health (NIMH) 13
China Spinal Cord Injury Network 5
Roxane Laboratories 4
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lithium Carbonate
Sponsor Trials
Other 123
NIH 28
Industry 17
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Johnson and Johnson
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.